SEC Form SC 13G filed by NanoString Technologies Inc.
$NSTG
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/27/2023 | Overweight → Neutral | JP Morgan | |
| 11/21/2023 | Outperform → Neutral | Robert W. Baird | |
| 7/5/2023 | $18.00 | Overweight | JP Morgan |
| 2/2/2023 | $15.00 | Buy | UBS |
| 3/24/2022 | $50.00 | Buy | Canaccord Genuity |
| 3/2/2022 | $85.00 → $70.00 | Overweight | JP Morgan |
JP Morgan downgraded NanoString Technologies from Overweight to Neutral
Robert W. Baird downgraded NanoString Technologies from Outperform to Neutral
JP Morgan resumed coverage of NanoString Technologies with a rating of Overweight and set a new price target of $18.00
Completed Exchange Transaction with Convertible Note Holders Representing 94% of Outstanding Principal – Record Q3 Revenue of $48.1 Million, 63% Year on Year Growth and Above Upper End of Q3 Guidance Range – NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. "The last few months have been extraordinar
- Record Q3 Revenue of Over $48 Million, 63% Year on Year Growth, Above Upper End of Q3 Guidance Range - - Implementing Reorganization of R&D and Manufacturing Operations to Improve Path to Profitability - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the third quarter ended September 30, 2023, as well as a reorganization designed to accelerate the Company's path to profitability. "Our teams delivered strong revenue results for the third quarter, with preliminary results exceeding consensus estimates and the high end of our guidance rang
– Record Q2 Revenue of $44.2 Million, 37% Year on Year Growth and Above Upper End of Q2 Guidance Range – - Retained More than $35 Million in CosMx Instrument Order Backlog at the End of Q2 - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June 30, 2023. "Strong growth in our spatial biology business and continued durability in our nCounter business helped us generate record revenue during the second quarter," said Brad Gray, President and CEO of NanoString. "We expect to continue to benefit from substantial CosMx instrument order backlog through
$47.5 Million in New Financing Secured from Existing Noteholders, Upsized from Initial $40 million Commitment Supports Mission to Continue Serving Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term loans to be funded upon entry of the final
Initiates Voluntary Chapter 11 Restructuring Proceedings with Additional $40 Million in Financing Secured from Existing Noteholders to Facilitate Process Continuing to Serve Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG) ("NanoString" or "the Company"), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to "Map the Universe of Biology." With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the
Three customers will present inaugural studies powered by the novel CosMx Whole Transcriptome Panel during annual AGBT meeting NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry's first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), NanoString and independent researchers will also highlight recently achieved whole transcriptome imag
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13G - NanoString Technologies Inc (0001401708) (Subject)
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for discovery and translational research, today announced that Todd Garland has been appointed Chief Commercial Officer, effective August 28, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230826560279/en/NanoString Appoints Todd Garland as Chief Commercial Officer (Photo: Business Wire) Mr. Garland is a senior executive with more than 25 years of experience in healthcare and life sciences technologies that serve customers in the discovery, translational and clinical markets. Most recently Mr. Garland served as Chief Commercial Officer at Cytek B
DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company's board of directors, effective July 18,2022. These appointments expand DermTech's board of directors to eight members. "We are excited to welcome Kirk and Mark as new independent directors," commented Matt Posard, DermTech's chairman. "They are both accomplished life science executives, with an established track record in building companies, business development, capital formation and strategic partnerships. Their perspectives in guiding high-growth co
Dr. Rob Hershberg steps down from Board after seven years of service NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the appointment of Dr. Teresa (Teri) Foy to the Board of Directors, effective April 18, 2022. "I am honored to welcome Dr. Foy to the team. Teri is a leader in immuno-oncology and cellular therapy, with decades of experience in pharmaceutical research," said president and chief executive officer Brad Gray. "Immunology and oncology are two of the most important applications for spatial biology, and Teri brings a wealth of knowledge in the ways that life science tools are utilized
8-K - NanoString Technologies Inc (0001401708) (Filer)
8-K - NanoString Technologies Inc (0001401708) (Filer)
8-K - NanoString Technologies Inc (0001401708) (Filer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
Gainers FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) shares increased by 25.0% to $17.43 during Tuesday's after-market session. Sonnet BioTherapeutics (NASDAQ:SONN) stock moved upwards by 13.46% to $1.77. The company's market cap stands at $5.4 million. GlucoTrack (NASDAQ:GCTK) stock rose 12.19% to $0.23. The company's market cap stands at $4.8 million. Clene (NASDAQ:CLNN) shares moved upwards by 9.92% to $0.47. The market value of their outstanding shares is at $59.7 million. Larimar Therapeutics (NASDAQ:LRMR) shares moved upwards by 8.69% to $9.5. The company's market cap stands at $417.1 million. BiomX (AMEX:PHGE) shares rose 6.83% to $0.24. The company's market cap stands at $
Shares of IPG Photonics Corporation (NASDAQ:IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. IPG Photonics posted GAAP earnings of 89 cents per share, versus market estimates of 95 cents per share. The company’s quarterly sales came in at $298.90 million versus expectations of $286.12 million. IPG Photonics shares dipped 11.2% to $92.06 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Ohmyhome Limited (NASDAQ:OMH) shares climbed 300% to $4.80. BioNexus Gene Lab Corp. (NASDAQ:BGLC) got a boost, surging 270% to $1.52. Digital Brands Group, Inc. (NASD
Gainers FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) shares rose 29.1% to $9.55 during Tuesday's regular session. Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 24.82% to $1.74. The company's market cap stands at $50.1 million. Bicycle Therapeutics (NASDAQ:BCYC) shares moved upwards by 23.42% to $21.5. The market value of their outstanding shares is at $810.8 million. Envoy Medical (NASDAQ:COCH) stock rose 20.15% to $1.55. The market value of their outstanding shares is at $30.3 million. Larimar Therapeutics (NASDAQ:LRMR) shares increased by 19.91% to $9.39. The market value of their outstanding shares is at $412.2 million. BioXcel Therapeutics (NASDAQ:BTAI) shares moved